AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.34 |
Market Cap | 5.17M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -7.24 |
PE Ratio (ttm) | -0.05 |
Forward PE | n/a |
Analyst | Hold |
Ask | 0.35 |
Volume | 133,530 |
Avg. Volume (20D) | 3,831,300 |
Open | 0.34 |
Previous Close | 0.35 |
Day's Range | 0.34 - 0.35 |
52-Week Range | 0.29 - 5.48 |
Beta | undefined |
About VRPX
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an inject...
Analyst Forecast
According to 3 analyst ratings, the average rating for VRPX stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 763.06% from the latest price.